Preparation and in vitro / in vivo evaluation of resveratrol-loaded carboxymethyl chitosan nanoparticles

Drug Delivery

Volumn 23, Issue 3, 2016, Pages 981-991

  Zu, Yuangang ^a   Zhang, Yin ^a   Wang, Weiguo ^a   Zhao, Xiuhua ^a   Han, Xue ^a   Wang, Kunlun ^a   Ge, Yunlong ^a  

^a NORTHEAST FORESTRY UNIVERSITY   (China)

Author keywords

Antioxidant; Bioavailability; Carboxymethyl chitosan; Nanoparticles; Resveratrol

Indexed keywords

CARBOXYMETHYL-CHITOSAN; CHITOSAN; DRUG CARRIER; NANOPARTICLE; POWDER; RESVERATROL; SOLVENT; STILBENE DERIVATIVE;

ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; CHEMISTRY; GASTROINTESTINAL TRACT; MALE; METABOLISM; PARTICLE SIZE; POWDER; RAT; SOLUBILITY; SPRAGUE DAWLEY RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; CHITOSAN; DRUG CARRIERS; GASTROINTESTINAL TRACT; MALE; NANOPARTICLES; PARTICLE SIZE; POWDERS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SOLVENTS; STILBENES;

EID: 84958176086     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.924167     Document Type: Article

References (17)

1. Baur JA, Sinclair DA. (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506
2. Dong W, Han B, Feng Y, et al. (2010). Pharmacokinetics and biodegradation mechanisms of a versatile carboxymethyl derivative of chitosan in rats: in vivo and in vitro evaluation. Biomacromolecules 11: 1527-33
3. Elzoghby AO, Samy WM, Elgindy NA. (2012). Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Rel 157: 168-82
4. Fu D, Han B, Dong W, et al. (2011). Effects of carboxymethyl chitosan on the blood system of rats. Biochem Biophys Res Commun 408: 110-14
5. Horan RL, Antle K, Collette AL, et al. (2005). In vitro degradation of silk fibroin. Biomaterials 26: 3385-93
6. Kreuter J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47: 65-81
7. Meyer AS, Yi O-S, Pearson DA, et al. (1997). Inhibition of human low-density lipoprotein oxidation in relation to composition of phenolic antioxidants in grapes (Vitis vinifera). J Agric Food Chem 45: 1638-43
8. Pace-Asciak CR, Hahn S, Diamandis EP, et al. (1995). The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 235: 207-19
9. Panagi Z, Beletsi A, Evangelatos G, et al. (2001). Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm 221: 143-52
10. Tahara K, Miyazaki Y, Kawashima Y, et al. (2011). Brain targeting with surface-modified poly(D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration. Eur J Pharm Biopharm 77: 84-8
11. Takeuchi H, Yamamoto H, Kawashima Y. (2001). Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 47: 39-54
12. Wang ZY, Song J, Zhang DS. (2009). Nanosized As2O3/Fe2O3 complexes combined with magnetic fluid hyperthermia selectively target liver cancer cells. World J Gastroenterol 15: 2995-3002
13. Watnasirichaikul S, Rades T, Tucker IG, Davies NM. (2002). Effects of formulation variables on characteristics of poly (ethylcyanoacrylate) nanocapsules prepared from w/o microemulsions. Int J Pharm 235: 237-46
14. Wenzel E, Somoza V. (2005). Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 49: 472-81
15. Wissing SA, Kayser O, Muller RH. (2004). Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56: 1257-72
16. Wu SL, Sun ZJ, Yu L, et al. (2004). Effect of resveratrol and in combination with 5-FU on murine liver cancer. World J Gastroenterol 10: 3048-52
17. Xiong S, Yu B, Wu J, et al. (2011). Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS. Biomed Pharmacother 65: 2-8